000283177 001__ 283177
000283177 005__ 20260129104043.0
000283177 0247_ $$2doi$$a10.1002/alz70856_105585
000283177 0247_ $$2pmid$$apmid:41512227
000283177 0247_ $$2pmc$$apmc:PMC12788821
000283177 0247_ $$2ISSN$$a1552-5260
000283177 0247_ $$2ISSN$$a1552-5279
000283177 037__ $$aDZNE-2026-00056
000283177 041__ $$aEnglish
000283177 082__ $$a610
000283177 1001_ $$0P:(DE-2719)9002917$$aErsözlü, Ersin$$b0$$udzne
000283177 1112_ $$aAlzheimer’s Association International Conference$$cToronto$$d2025-07-27 - 2025-07-31$$gAAIC 25$$wCanada
000283177 245__ $$aAn explorative analyses of in vivo plasma marker alterations in relation to imaging and neuropathological indicators of cerebral amyloid angiopathy
000283177 260__ $$c2025
000283177 3367_ $$0PUB:(DE-HGF)1$$2PUB:(DE-HGF)$$aAbstract$$babstract$$mabstract$$s1769600857_29843
000283177 3367_ $$033$$2EndNote$$aConference Paper
000283177 3367_ $$2BibTeX$$aINPROCEEDINGS
000283177 3367_ $$2DRIVER$$aconferenceObject
000283177 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$mjournal
000283177 3367_ $$2DataCite$$aOutput Types/Conference Abstract
000283177 3367_ $$2ORCID$$aOTHER
000283177 520__ $$aAlzheimer's disease (AD) is one of the most prevalent causes of dementia, while concomitant diseases such as cerebral amyloid angiopathy (CAA) has a substantial impact on clinical trajectories and therapy, i.e. risk factor for imaging abnormalities under anti-amyloid antibodies. As there are no established biomarkers to identify individual with CAA, we aim to explore potential plasma biomarkers for mechanisms related to CAA in participants in continuum of AD.We included a total of 47 participants from the AD Neuroimaging Initiative study with available plasma biomarkers from a multiplex immunoassay panel (n = 145 analytes from 'Biomarkers Consortium MRM data', consisting of proteins related to cancer, cardiovascular disease, metabolic disorders, inflammation, and AD). We stratified the cohort into participants with either T2*-GRE magnetic resonance images (MRI) (n = 21) at baseline or postmortem neuropathological assessment (n = 26). The numbers of definite lobar microbleeds were obtained from central visual readings (Mayo Clinic, Jack Lab), while central neuropathological severity scales for AD (AD neuropathologic change) and CAA (overall neocortical amyloid angiopathy) were included. We defined CAA status as at least two lobar microbleeds in orientation to the Boston criteria and at least moderate density in neuropathology. Plasma analytes were measured twice with a one-year time difference with a maximum of 6.6 years prior to either first MRI or time of death. Non-parametric receiver operating characteristic curves and area under the curve (AUC) values of analytes in differentiation of CAA status.In both cohorts with imaging and NP data, most of the participants exhibited cognitive symptoms and revealed in vivo or neuropathological changes regarding AD (Table-1). Using the imaging, various markers related to inflammation, lipid metabolism, cell adhesion, and sex steroids are found to show a constant increase in CAA (Table-2, Figure 1). Moreover, we identified increases in Clusterin and Complement Factor H levels as well as reduced Alpha-Fetoprotein, characterizing the neuropathological definition of CAA (Table-2, Figure 1).Using both ante-mortem and post-mortem indicators of CAA, several candidate plasma biomarkers of CAA have been found, whereas replications in bigger samples with multiple measurements are crucial to address confounder factors and temporal relationships.
000283177 536__ $$0G:(DE-HGF)POF4-353$$a353 - Clinical and Health Care Research (POF4-353)$$cPOF4-353$$fPOF IV$$x0
000283177 588__ $$aDataset connected to CrossRef, PubMed, , Journals: pub.dzne.de
000283177 650_7 $$2NLM Chemicals$$aBiomarkers
000283177 650_2 $$2MeSH$$aHumans
000283177 650_2 $$2MeSH$$aBiomarkers: blood
000283177 650_2 $$2MeSH$$aMale
000283177 650_2 $$2MeSH$$aFemale
000283177 650_2 $$2MeSH$$aAlzheimer Disease: blood
000283177 650_2 $$2MeSH$$aAlzheimer Disease: pathology
000283177 650_2 $$2MeSH$$aAlzheimer Disease: diagnostic imaging
000283177 650_2 $$2MeSH$$aAged
000283177 650_2 $$2MeSH$$aMagnetic Resonance Imaging
000283177 650_2 $$2MeSH$$aCerebral Amyloid Angiopathy: blood
000283177 650_2 $$2MeSH$$aCerebral Amyloid Angiopathy: pathology
000283177 650_2 $$2MeSH$$aCerebral Amyloid Angiopathy: diagnostic imaging
000283177 650_2 $$2MeSH$$aAged, 80 and over
000283177 650_2 $$2MeSH$$aCohort Studies
000283177 650_2 $$2MeSH$$aBrain: pathology
000283177 650_2 $$2MeSH$$aBrain: diagnostic imaging
000283177 7001_ $$0P:(DE-2719)9003016$$aHellmann-Regen, Julian$$b1$$eLast author$$udzne
000283177 773__ $$0PERI:(DE-600)2201940-6$$a10.1002/alz70856_105585$$gVol. 21 Suppl 2, no. Suppl 2, p. e105585$$nSuppl 2$$pe105585$$tAlzheimer's and dementia$$v21 Suppl 2$$x1552-5260$$y2025
000283177 8564_ $$uhttps://pub.dzne.de/record/283177/files/DZNE-2026-00056.pdf$$yOpenAccess
000283177 8564_ $$uhttps://pub.dzne.de/record/283177/files/DZNE-2026-00056.pdf?subformat=pdfa$$xpdfa$$yOpenAccess
000283177 909CO $$ooai:pub.dzne.de:283177$$popenaire$$popen_access$$pVDB$$pdriver$$pdnbdelivery
000283177 9101_ $$0I:(DE-HGF)0$$6P:(DE-2719)9002917$$aExternal Institute$$b0$$kExtern
000283177 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)9003016$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b1$$kDZNE
000283177 9131_ $$0G:(DE-HGF)POF4-353$$1G:(DE-HGF)POF4-350$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lNeurodegenerative Diseases$$vClinical and Health Care Research$$x0
000283177 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2025-01-06
000283177 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2025-01-06
000283177 915__ $$0LIC:(DE-HGF)CCBY4$$2HGFVOC$$aCreative Commons Attribution CC BY 4.0
000283177 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bALZHEIMERS DEMENT : 2022$$d2025-01-06
000283177 915__ $$0StatID:(DE-HGF)3001$$2StatID$$aDEAL Wiley$$d2025-01-06$$wger
000283177 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2025-01-06
000283177 915__ $$0StatID:(DE-HGF)9910$$2StatID$$aIF >= 10$$bALZHEIMERS DEMENT : 2022$$d2025-01-06
000283177 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2025-01-06
000283177 915__ $$0StatID:(DE-HGF)0510$$2StatID$$aOpenAccess
000283177 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2025-01-06
000283177 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine$$d2025-01-06
000283177 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2025-01-06
000283177 9201_ $$0I:(DE-2719)1811005$$kAG Endres$$lInterdisciplinary Dementia Research$$x0
000283177 980__ $$aabstract
000283177 980__ $$aVDB
000283177 980__ $$aUNRESTRICTED
000283177 980__ $$ajournal
000283177 980__ $$aI:(DE-2719)1811005
000283177 9801_ $$aFullTexts